Evidence map›Paper›PMID 35905130›Full record

ArticlePloS one2022

Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America.

Rita Mariel Correa, Armando Baena, Joan Valls, María Celeste Colucci, Laura Mendoza, Maryluz Rol, Carolina Wiesner, Annabelle Ferrera, María Dolores Fellner, Joaquín Víctor González and 16 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Effectiveness ofThe Journal of international medical research · 2025
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Characterization of Three Novel Papillomavirus Genomes in Vampire Bats (Animals : an open access journal from MDPI · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 12 institutions in 10 countries.

Rita Mariel CorreaServicio Virus Oncogénicos, Laboratorio Nacional y Regional de Referencia de HPV, Instituto Nacional de Enfermedades Infecciosas- ANLIS "Dr. Malbrán", Buenos Aires, Argentina.ORCID 0000-0002-8241-1924
Armando BaenaEarly Detection, Prevention & Infections Branch, International Agency for Research on Cancer, World Health Organization, Lyon, France.ORCID 0000-0001-8717-6911
Joan VallsEarly Detection, Prevention & Infections Branch, International Agency for Research on Cancer, World Health Organization, Lyon, France.
María Celeste ColucciServicio Virus Oncogénicos, Laboratorio Nacional y Regional de Referencia de HPV, Instituto Nacional de Enfermedades Infecciosas- ANLIS "Dr. Malbrán", Buenos Aires, Argentina.
Laura MendozaInstituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción, San Lorenzo, Paraguay, San Lorenzo, Paraguay.
Maryluz RolEarly Detection, Prevention & Infections Branch, International Agency for Research on Cancer, World Health Organization, Lyon, France.
Carolina WiesnerInstituto Nacional de Cancerología, Bogotá, Colombia.
Annabelle FerreraInstituto de Investigaciones en Microbiología, Universidad Nacional Autónoma de Honduras, Tagucigalpa, Honduras.
María Dolores FellnerServicio Virus Oncogénicos, Laboratorio Nacional y Regional de Referencia de HPV, Instituto Nacional de Enfermedades Infecciosas- ANLIS "Dr. Malbrán", Buenos Aires, Argentina.
Joaquín Víctor GonzálezServicio Virus Oncogénicos, Laboratorio Nacional y Regional de Referencia de HPV, Instituto Nacional de Enfermedades Infecciosas- ANLIS "Dr. Malbrán", Buenos Aires, Argentina.
Jorge Alejandro BasilettiServicio Virus Oncogénicos, Laboratorio Nacional y Regional de Referencia de HPV, Instituto Nacional de Enfermedades Infecciosas- ANLIS "Dr. Malbrán", Buenos Aires, Argentina.
Pamela MongelosInstituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción, San Lorenzo, Paraguay, San Lorenzo, Paraguay.
Mercedes Rodriguez de la PeñaServicio Ginecología, Hospital Nacional "Prof. Posadas", El Palomar, Argentina.
Agustina SainoSección Histología, Servicio Anatomía Patológica, Hospital Nacional "Prof. Posadas", El Palomar, Argentina.
Elena KasamatsuInstituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción, San Lorenzo, Paraguay, San Lorenzo, Paraguay.
Carlos VelardeInstituto Nacional de Enfermedades Neoplásicas, Surquillo, Perú.
Ninoska MacavilcaInstituto Nacional de Enfermedades Neoplásicas, Surquillo, Perú.
Sandra MartinezInstituto Nacional de Cancerología, Bogotá, Colombia.
Gino VenegasClínica Anglo Americana, Lima, Perú.ORCID 0000-0002-4114-0291
Alejandro CalderónCaja Costarricense de Seguro Social, Región Pacífico Central, San José, Costa Rica.
Guillermo RodriguezComisión Honoraria de Lucha contra el Cáncer, Montevideo, Uruguay.
Hernán BarriosInstituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción, San Lorenzo, Paraguay, San Lorenzo, Paraguay.
Rolando HerreroAgencia Costarricense de Investigaciones Biomédicas, San José, Costa Rica.
Maribel AlmonteEarly Detection, Prevention & Infections Branch, International Agency for Research on Cancer, World Health Organization, Lyon, France.
María Alejandra PicconiServicio Virus Oncogénicos, Laboratorio Nacional y Regional de Referencia de HPV, Instituto Nacional de Enfermedades Infecciosas- ANLIS "Dr. Malbrán", Buenos Aires, Argentina.
ESTAMPA Study Group
Administración Nacional de Laboratorios e Institutos de Salud · ARUniversidad Nacional de Asunción · PYCentre international de recherche sur le cancer · FRHospital Posadas · ARInstituto Nacional de Cancerología · COInstituto Nacional de Enfermedades Neoplásicas · PEAnglo American (United Kingdom) · GBCentro de Investigación Biomédica en Red de Cáncer · ESComisión Honoraria de Lucha contra el cáncer · UYCosta Rican Department of Social Security · CRInstituto Costarricense de Investigación y Enseñanza en Nutrición y Salud · CRNational Autonomous University of Honduras · HN

Funding

Development and clinical validation of a multi-type HPV E6/E7 oncoprotein test for cervical cancer screening and triage in low- and middle-income countriesUH3CA202730 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI ALMONTE, MARIBEL · 2019 to 2021
$2.8M
NCI NIH HHS UH3 CA202730World Health Organization 001
6 · The paper itself

Abstract

The proportion of HPV16 and 18-associated cervical cancer (CC) appears rather constant worldwide (≥70%), but the relative importance of the other HR-HPV differs slightly by geographical region. Here, we studied the HPV genotype distribution of HPV positive Latin American (LA) women by histological grade, in a sub-cohort from the ESTAMPA study; we also explored the association of age-specific HPV genotypes in severe lesions. Cervical samples from 1,252 participants (854 ≤CIN1, 121 CIN2, 194 CIN3 and 83 CC) were genotyped by two PCRs-Reverse Blotting Hybridization strategies: i) Broad-Spectrum General Primers 5+/6+ and ii) PGMY9/11 PCRs. HPV16 was the most frequently found genotype in all histological grades, and increased with the severity of lesions from 14.5% in ≤ CIN1, 19.8% in CIN2, 51.5% in CIN3 to 65.1% in CC (p < 0.001). For the remaining HR-HPVs their frequency in CC did not increase when compared to less severe categories. The nonavalent vaccine HR-types ranked at the top in CC, the dominant ones being HPV16 and HPV45. HR-HPV single infection occurs, respectively, in 57.1% and 57.0% of ≤CIN1 and CIN2, increasing to 72.2% and 91.6% in CIN3 and CC (p<0.001). No association between age and HPV type was observed in CC, although the risk of HPV16 infection in CIN3 cases increased with age. Results confirm the relevance of HPV16 in the whole clinical spectrum, with a strong rise of its proportion in CIN3 and cancer. This information will be relevant in evaluating the impact of HPV vaccination, as a baseline against which to compare genotype changes in HPV type-specific distribution as vaccinated women participate in screening in LA region. Likewise, these data may help select the best HPV testing system for HPV-based efficient, affordable, and sustainable screening programmes.

Indexed as

Papillomavirus InfectionsUterine Cervical DysplasiaUterine Cervical NeoplasmsFemaleGenotypeHuman papillomavirus 16HumansLatin AmericaPapillomaviridae

Identifiers

PMID35905130
PMCPMC9337688
OpenAlexW4288715280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.